NKG2D-CAR memory T cell / University Hospital La Paz - LARVOL DELTA

TRIAL IN PROGRESS: A PHASE I TRIAL OF MEMORY T CELLS EXPRESSING AN NKG2D CAR IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH ADVANCED SARCOMA (EBMT 2026) - P1 | " We are currently recruiting for a phase I trial (CAR4SARC), that is an open-label, single-center, non-randomized, dose-escalation study to determine the dose-limiting toxicity and maximum tolerated dose of systemic (Arm A, n=9) and combined systemic and intratumoral (Arm B, n=9) donor-derived NKG2D-CAR memory T cell infusions... Overall, the results suggest that the administration of allogeneic NKG2D-CAR CD45RA⁻ T cells is feasible and demonstrates an acceptable safety profile in pediatric and AYA patients with relapsed or refractory sarcomas without any GvHD. Although clinical efficacy was limited in this heavily pretreated population, with early disease progression, no toxicities attributable to the allogeneic CAR T-cell product required treatment discontinuation. These findings indicate that selective use of a memory T-cell population (CD45RA⁻) for allogeneic CAR T-cell manufacturing may mitigate the risk of adverse events and supports the continued exploration..."

Clinical • Metastases • P1 data • Ewing Sarcoma • Graft versus Host Disease • Hematological Disorders • Immunology • Leukopenia • Osteosarcoma • Rhabdomyosarcoma • Sarcoma • Solid Tumor • NKG2D

CAR4SAR: A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults With Advanced Sarcoma (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Antonio Pérez Martínez | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Sarcoma • Solid Tumor • NKG2D • ULBP2